Business
Currency:CNY
2023/FY
Stock NameRevenueRatio
药品销售及特许权使用费收入195.55M89.38%
提供用于研发项目的货品╱消耗品收入14.72M6.73%
许可费收入7.2M3.29%
合作开发及商业化收入873K0.40%
合约生产机构收入426K0.19%
Product
No Data
Region
Currency:CNY
2019/H1
Stock NameRevenueRatio
China9.92M90.00%
Other areas1.1M10.00%